Source: Business Insider
Martin Shkreli, the hedge fund manager who triggered an outcry by putting a 5,000 percent markup on its lifesaving drug, has gone to war with business news channel CNBC, reports Dylan Byers of CNNMoney.
Byers writes, “According to CNBC host Scott Wapner, Shkreli wanted to come on CNBC to defend another drug company, Valeant Pharmaceuticals, against accusations of accounting fraud. CNBC told Shkreli they would also have to talk to him about the elephant in the room — his decision to jack up the price of the toxoplasmosis drug Daraprim from $18 a pill to $750 a pill. He said no.
“Shkreli tells a slightly different version: CNBC had asked him to come on and talk about Valeant, then said they wanted to talk about Turing Pharmaceuticals as well. ‘I tell them to pound sand,’ Shkreli wrote on Twitter.
“Shkreli instead went to Fox Business Network on Friday morning, where he defended his price gouging in an interview with Maria Bartiromo.”
Read more here.
Former Business Insider executive editor Rebecca Harrington has been hired by Dynamo to be its…
Bloomberg Television has hired Brenda Kerubo as a desk producer in London. She will be covering Europe's…
In a meeting at CNBC headquarters Thursday afternoon, incoming boss Mark Lazarus presented a bullish…
Ritika Gupta, the BBC's North American business correspondent, was interviewed by Global Woman magazine about…
Rest of World has hired Kinling Lo as a China reporter. Lo was previously a…
Bloomberg News saw strong unique visitor growth to its website in October, passing Fox Business…
View Comments
If this doofus doesn't yet realize that he will always be asked about daraprim, and that it will be in the first sentence of his obituary, he is far too stupid to run any hedge fund that includes my money. Some acts simply define us, sir.